Literature DB >> 7191713

Plasminogen activator in cultured Lewis lung carcinoma cells measured by chromogenic substrate assay.

P Whur, M Magudia, J Boston, J Lockwood, D C Williams.   

Abstract

A chromogenic substrate assay for the plasminogen activator (PA) activity of Lewis lung carcinoma cells has been developed. The cells were incubated with plasminogen, the activation of which to plasmin was measured by the amidolysis of the chromogenic substrate S-2251. This was routinely performed as a 4h serum-free assay, but a variation lasting 24 h, in medium supplemented with plasminogen-free inhibitor-reduced serum, produced similar results. The assay also detected PA released into the medium. PA activity was proportional to cell density, and the assay was non-toxic to the cells. Assays were performed on cultures derived from primary and metastatic tumours. Host cells were effectively eliminated from such cultures but, because of an initial phase of tumour-cell death, PA assays were not carried out until cultures became established. No consistent difference was detected between PA levels in primary and metastatic cultures. However, these cultures were shown to be atypical of the parent tumour; they grew slowly when reinjected at the primary site, and their metastatic potential was impaired.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7191713      PMCID: PMC2010387          DOI: 10.1038/bjc.1980.231

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Fibrin overlay methods for the detection of single transformed cells and colonies of transformed cells.

Authors:  P Jones; W Benedict; S Strickland; E Reich
Journal:  Cell       Date:  1975-07       Impact factor: 41.582

2.  Differentiation of early mouse embryonic and teratocarcinoma cells in vitro: plasminogen activator production.

Authors:  M I Sherman; S Strickland; E Reich
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

3.  Increased protease levels in transformed cells: a casein overlay assay for the detection of plasminogen activator production.

Authors:  A R Goldberg
Journal:  Cell       Date:  1974-06       Impact factor: 41.582

4.  Selection of successive tumour lines for metastasis.

Authors:  I J Fidler
Journal:  Nat New Biol       Date:  1973-04-04

5.  The rapid fibrin plate - a method for plasminogen activator assay.

Authors:  N A Marsh; P J Gaffney
Journal:  Thromb Haemost       Date:  1977-08-31       Impact factor: 5.249

6.  Designing of peptide substrates. Different approaches exemplified by new chromogenic substrates for kallikreins and urokinase.

Authors:  G Claeson; L Aurell; P Friberger; S Gustavsson; G Karlsson
Journal:  Haemostasis       Date:  1978

7.  Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumours.

Authors:  H Peterson
Journal:  Cancer Treat Rev       Date:  1977-09       Impact factor: 12.111

8.  Secretion of plasminogen activator by stimulated macrophages.

Authors:  J C Unkeless; S Gordon; E Reich
Journal:  J Exp Med       Date:  1974-04-01       Impact factor: 14.307

9.  Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation.

Authors:  T C Stephens; J H Peacock; G G Steel
Journal:  Br J Cancer       Date:  1977-07       Impact factor: 7.640

10.  Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration.

Authors:  L Ossowski; J P Quigley; G M Kellerman; E Reich
Journal:  J Exp Med       Date:  1973-11-01       Impact factor: 14.307

View more
  6 in total

Review 1.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

Authors:  J E Testa; J P Quigley
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

2.  Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.

Authors:  S Pereyra-Alfonso; G R Solarz; E Bal de Kier Joffé
Journal:  Clin Exp Metastasis       Date:  1992-11       Impact factor: 5.150

3.  Paracrine control of differentiation in the alveolar carcinoma, A549, by human foetal lung fibroblasts.

Authors:  V Speirs; K P Ray; R I Freshney
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

4.  Interrelationship between differentiation and malignancy-associated properties in glioma.

Authors:  M C Frame; R I Freshney; P F Vaughan; D I Graham; R Shaw
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

5.  Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.

Authors:  L Skriver; L I Larsson; V Kielberg; L S Nielsen; P B Andresen; P Kristensen; K Danø
Journal:  J Cell Biol       Date:  1984-08       Impact factor: 10.539

6.  Activity of interferon alpha, interleukin 6 and insulin in the regulation of differentiation in A549 alveolar carcinoma cells.

Authors:  C McCormick; R I Freshney; V Speirs
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.